Lipid nanoparticles for oral delivery of raloxifene: Optimization, stability, in vivo evaluation and uptake mechanism

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 1, 2014, Pages 114-124

  Ravi, Punna Rao ^a   Aditya, N ^a   Kathuria, Himanshu ^a   Malekar, Srinivas ^a   Vats, Rahul ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Box Bhenken design; Design of experiments; Everted gut sac; Glyceryl behenate; Lymphatic transport; Raloxifene HCl; Solid lipid nanoparticle

Indexed keywords

CLATHRIN; CYCLOHEXIMIDE; DRUG CARRIER; GLYCEROL DERIVATIVE; GLYCERYL TRIBEHENATE; RALOXIFENE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; FATTY ACID; GLYCEROL BEHENATE; NANOPARTICLE; POLOXAMER; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CAVEOLA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; IN VIVO STUDY; LYMPHATIC SYSTEM; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; WISTAR RAT; ANIMAL; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FATTY ACIDS; FEMALE; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; RALOXIFENE; RATS, WISTAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84901610423     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.12.015     Document Type: Article

References (42)

1. World Health Organization, Prevention and management of osteoporosis, Report of a WHO scientific group, World Health Organ Tech Rep Ser. 921 (2003) 1-164.
2. J. Stevenson, and M. Marsh Epidemiology John C. Stevenson, Michael S. Marsh, An Atlas of Osteoporosis 2008 Informa Healthcare United Kingdom 1 8
3. J. Kanis, Assessment of osteoporosis at the primary health care level, Technical Report, World Health Organization Collaborating Centre for Metabolic Bone Diseases (2007) 6-9.
4. O. Johnell, and J. Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos. Int. 17 2006 1726 1733 (Pubitemid 44607392)
5. R. Jose, C. Eduardo, R. Maria, C. Emilio, Á. Angel, and C. Marta Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice Open Orthop. J. 3 2009 14 21
6. D. Hochner-Celnikier Pharmacokinetics of raloxifene and its clinical application Eur. J. Obstet. Gynecol. Reprod. Biol. 85 1999 23 29 (Pubitemid 29248779)
7. T. Lindstrom, N. Whitaker, and G. Whitaker Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys Xenobiotica 14 1984 841 847 (Pubitemid 15180639)
8. T. Deguchi, N. Watanabe, A. Kurihara, K. Igeta, H. Ikenaga, K. Fusegawa, N. Suzuki, S. Murata, M. Hirouchi, Y. Furuta, M. Iwasaki, O. Okazaki, and T. Izumi Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach Drug Metab. Dispos. 39 2011 820 829
9. H. Thörn, M. Yasin, P. Dickinson, and H. Lennernäs Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery Xenobiotica 42 2012 917 928
10. T. Mizuma Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10 Int. J. Pharm. 378 2009 140 141
11. T. Tran, B. Poudel, N. Marasini, S. Chi, H. Choi, C. Yong, and J. Kim Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent Int. J. Pharm. 443 2013 50 57
12. H. Thakkar, J. Nangesh, M. Parmar, and D. Patel Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system J. Pharm. Bioallied Sci. 3 2011 442 448
13. M. Wempe, V. Wacher, K. Ruble, M. Ramsey, K. Edgar, N. Buchanan, and C. Buchanan Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin Int. J. Pharm. 346 2008 25 37 (Pubitemid 350110509)
14. M. Burra, R. Jukanti, K. Janga, S. Sunkavalli, A. Velpula, S. Ampati, and K. Jayaveera Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles Adv. Powder Technol. 24 2013 393 402
15. R. Müller, D. Rühl, and S. Runge Biodegradation of solid lipid nanoparticles as a function of lipase incubation time Int. J. Pharm. 144 1996 115 121 (Pubitemid 27039349)
16. T. Göppert, and R. Müller Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting Int. J. Pharm. 302 2005 172 186 (Pubitemid 41242762)
17. B. Singh, Kumar, and N. Ahuja Optimizing drug delivery using systematic "design of experiments". Part I: fundamental aspects Crit. Rev. Ther. Drug 22 2004 27 105
18. Comparisons of Response Surface Designs. < http://www.itl.nist.gov/ div898/handbook/pri/section3/pri3363.htm > (accessed 03.03.13).
19. F. Castelli, C. Puglia, M. Sarpietro, L. Rizza, and F. Bonina Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry Int. J. Pharm. 304 2005 231 238 (Pubitemid 41427665)
20. P. Ravi, N. Aditya, and R. Vats Development, validation and pharmacokinetic application of liquid chromatographic method for estimation of raloxifene hydrochloride in rabbit plasma Acta Chromatogr. 24 2012 559 573
21. F. Liu, J. Kuo, K. Sung, and O. Hu Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies Int. J. Pharm. 257 2003 23 31 (Pubitemid 36507029)
22. T. Hickey, D. Kreutzer, D. Burgess, and F. Moussy Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices Biomaterials 23 2002 1649 1656 (Pubitemid 34158587)
23. M. Barzegar-Jalali, K. Adibkia, H. Valizadeh, M. Shadbad, A. Nokhodchi, Y. Omidi, G. Mohammadi, S. Nezhadi, and M. Hasan Kinetic analysis of drug release from nanoparticles J. Pharm. Pharm. Sci. 11 2008 167 177
24. ICH Q 1 A (R2). Stability Testing of New Drug Substances and Products. < http://www.emea.eu.int/pdfs/human/ich/273699en.pdf >.
25. L. Barthe, M. Bessouet, J. Woodley, and G. Houin The improved everted gut sac: a simple method to study intestinal P-glycoprotein Int. J. Pharm. 173 1998 255 258
26. L. Barthe, J. Woodley, and G. Houin Gastrointestinal absorption of drugs: methods and studies Fundam. Clin. Pharmacol. 13 1999 154 168 (Pubitemid 32324243)
27. C. Porter, N. Trevaskis, and W. Charman Lipids and lipid based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 6 2007 231 248 (Pubitemid 46344627)
28. G. Sahay, D. Alakhova, and A. Kabanov Endocytosis of nanomedicines J. Controlled Release 145 2010 182 195
29. E. Roger, F. Lagarce, E. Garcion, and J. Benoit Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery Nanomedicine (London) 5 2010 287 306
30. E. Roger, F. Lagarce, E. Garcion, and J. Benoit Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle mediated transcytosis J. Controlled Release 140 2009 174 181
31. A. Khan, J. Mudassir, N. Mohtar, and Y. Darwis Advanced drug delivery to the lymphatic system: lipid-based nanoformulations Int. J. Nanomed. 8 2013 2733 2744
32. A. Dahan, and A. Hoffman Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs Eur. J. Pharm. Sci. 24 2005 381 388 (Pubitemid 40283521)
33. M. Lind, J. Jacobsen, R. Holm, and A. Müllertz Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80 Eur. J. Pharm. Sci. 35 2008 211 218
34. F. Gao, Z. Zhang, H. Bu, Y. Huang, Z. Gao, J. Shen, C. Zhao, and Y. Li Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism J. Controlled Release 149 2011 168 174
35. Z. Zhang, F. Gao, H. Bu, J. Xiao, and Y. Li Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats Nanomedicine 8 2012 740 747
36. J. Leroux, E. Allemann, E. Doelker, and R. Gurny New approach for the preparation of nanoparticles by an emulsification-diffusion method Eur. J. Pharm. Biopharm. 41 1994 14 18
37. J. Hao, X. Fang, Y. Zhou, J. Wang, F. Guo, F. Li, and X. Peng Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design Int. J. Nanomed. 6 2011 683 692
38. Y. Yang, T. Chung, X. Bai, and W. Chan Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method Chem. Eng. Sci. 55 2000 2223 2236 (Pubitemid 30233954)
39. S. Mayank, C. Krishna, A. Mishra, and K. Pathak Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies Drug Dev. Ind. Pharm. 37 2011 526 537
40. E. Souto, S. Wissing, C. Barbosa, and R. Müller Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery Int. J. Pharm. 278 2004 71 77 (Pubitemid 38670438)
41. R. Müller, R. Shegokar, and C. Keck 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications Curr. Drug Discovery Technol. 8 2011 207 227
42. S. Moghimi, A. Hunter, and T. Andresen Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective Annu. Rev. Pharmacol. Toxicol. 52 2012 481 503